Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems

News provided by

Sep 19, 2014, 09:55 ET

CORAL SPRINGS, Florida, September 19, 2014 /PRNewswire/ --

Biotech companies make announcements illustrating significant progress in medical technology, development of emerging drug systems and advanced Laboratory Instrumentation. Companies in focus today are: (OTC: PBIO), Benton, Dickinson and Company (NYSE: BDX), Thermo Fisher Scientific Inc. (NYSE: TMO), Regado Biosciences Inc. (NASDAQ: RGDO), Sangamo Biosciences Inc. (NASDAQ: SGMO) and Hologic Inc. (NASDAQ: HOLX)

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced it has received and approved all parts required to build nine high throughput Barozyme HT48 instruments and has begun to manufacture the new PCT-based instrument system. The Company believes the first instrument will be ready for shipment by mid-October and that additional Barozyme instruments will be built and released at a rate of about one per week thereafter.

The bench-top Barozyme HT48 is a first-in-class, high throughput PCT-based instrument. It is capable of processing up to 48 samples simultaneously using the Company's new and proprietary BaroFlex 8-well processing strips. The BaroFlex strips were designed and manufactured to the industry-standard micro-titer plate format, which the Company believes will allow the new Barozyme HT48 system to seamlessly integrate with the automated, standardized, high throughput liquid handling robotic and analytical systems installed in tens of thousands of biological research laboratories worldwide.

Read the full PBIO press release at http://www.financialnewsmedia.com/profiles/pbio.html

Dr. Nathan P. Lawrence, Vice President of Marketing and Sales, said: "the Barozyme HT48 was specifically designed for rapid, high quality enzymatic digestion of proteins, a universally important procedure conducted in thousands of laboratories worldwide. The ability of the Barozyme HT48 to process up to 48 samples simultaneously in a "microplate" format is a major improvement in the ergonomics of sample handling and a key step towards automation of PCT-based biological sample preparation. The new BaroFlex format of disposable sample containers in strips of eight processing wells not only lowers the total cost per sample processed by PCT but improves the sample handling and user experience. Lastly, the Barozyme HT48's flexible computer control was designed with GLP compliance in mind to meet specific demands of biopharmaceutical quality control and clinical proteomics." PBIO expects to build and ship nine Instrument Systems for evaluation between mid-October and late November and believes one or more systems will be purchased by the evaluating laboratories, impacting Q4 2014 Revenue.

Benton, Dickinson and Company (NYSE: BDX), a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. This segment's products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles used in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. On Thursday, BDX closed up .43% on over 828,000 shares traded.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has appointed three new members to its Scientific Advisory Board: Dr. Andrea Califano, Dr. Arnold J. Levine and Dr. Aviv Regev. Dr. Califano is the founding chairman of the department of systems biology at Columbia University, and he currently serves on the board of scientific advisors of the National Cancer Institute. He is also professor of biomedical informatics at Columbia University. Dr. Levine is professor emeritus of systems biology at the Institute for Advanced Study in Princeton, N.J. and professor of pediatrics and of biochemistry with the Robert Wood Johnson Medical School at Rutgers, the State University of New Jersey. Dr. Regev is a core member of the Broad Institute and an associate professor of biology at the Massachusetts Institute of Technology. She is also an investigator at the Howard Hughes Medical Institute.

Regado Biosciences Inc. (NASDAQ: RGDO) a biopharmaceutical company, focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications. The company's lead product includes REG1, an anticoagulant that is in Phase 2b clinical trial for use in patients with various cardiovascular conditions undergoing percutaneous coronary intervention. Its other product candidates under development also comprise REG2, which is in Phase 1 clinical trial for the treatment of venous thrombosis indication; and REG3, a preclinical stage antiplatelet therapy consisting of glycoprotein VI inhibitor for diabetic vasculopathy and other inflammatory diseases. On Thursday, RGDO closed down .95% on over 846,000 shares traded.

Sangamo Biosciences Inc. (NASDAQ: SGMO) recently announced plans to submit an Investigational New Drug (IND) application for the treatment of hemophilia B in the second quarter of 2015. This program, partnered with Shire, is the first therapeutic application of Sangamo's zinc finger nuclease (ZFN)-mediated In Vivo Protein Replacement Platform (IVPRP). Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient. "Shire has been impressed by the rapid progress of the novel hemophilia B program developed by Sangamo," said Albert Seymour, Ph.D., Senior Vice President and Head of Global Research and Nonclinical Development at Shire. "The Shire team continues to work very closely with Sangamo to submit the IND package to support this program."

Hologic Inc. (NASDAQ: HOLX) recently announced that its 3D mammography system (Hologic Selenia Dimensions 3D Breast Tomosynthesis) was named "Best in KLAS" in the digital mammography category based on the results of an annual independent survey of healthcare executives and clinicians by KLAS Research. The "2014 Best in KLAS: Medical Equipment and Infrastructure" report examined over 100 products in 23 different medical equipment and infrastructure categories. Hologic 3D Mammography received the highest performance rating, a 95.2 on a scale of 1 to 100, of all the products evaluated in all 23 categories. Hologic's 2D mammography system placed second in the digital mammography category. It is the third consecutive year that Hologic 3D and 2D digital mammography systems have held the first and second place rankings, and the fifth year in a row that a Hologic mammography product has held first place in the digital mammography category. Hologic's 3D Mammography system consistently outperformed the digital mammography market segment average in the five key performance measures used to evaluate systems in this category: sales and contracting; implementation and training; functionality and upgrades; service and support; and general.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by Pressure BioSciences, Inc. by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email: [email protected]
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group, LLC